Head-to-head evidence
INS068 vs SAR341402
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline
INS068
Developed by Jiangsu Hengrui Pharmaceuticals
NCT05699408 · Phase 3 · completed
This Phase 3 trial randomly assigned 513 people with type 2 diabetes to insulin sudelidec or to insulin glargine, alongside their existing oral diabetes medicines. It was open-label, so treatment assignment was known throughout. HbA1c fell by 1.34 percentage points on insulin sudelidec against 1.37 on insulin glargine, a difference of 0.02 points (95% CI -0.14 to 0.18), meeting the prespecified test that it was not worse than glargine.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
SAR341402
Marketed by Sanofi
NCT03211858 · Phase 3 · completed
The trial randomized 597 participants to SAR341402 or active-control NovoLog/NovoRapid, but treatment assignment was not blinded. The primary HbA1c endpoint met the prespecified non-inferiority margins, while HbA1c is a surrogate measure, so the evidence is considered moderate rather than strong.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: INS068's landscape · SAR341402's landscape